Worsening physical functioning in patients with neuroinflammatory disease during the COVID-19 pandemic

Mult Scler Relat Disord. 2022 Feb:58:103482. doi: 10.1016/j.msard.2021.103482. Epub 2022 Jan 4.

Abstract

Objective: To quantify changes in psychological wellbeing and physical function as reported by people with neurological inflammatory disease (PwNID) during the COVID-19 pandemic.

Methods: 1134 PwNID and 868 control participants were recruited through five major academic medical centers in the Northeast/Mid-Atlantic U.S. beginning in April 2020. Participants completed serial surveys throughout the COVID-19 pandemic that aimed to quantify mood symptoms and physical function, analyzed cross-sectionally with a smaller cohort analyzed longitudinally.

Results: Throughout the pandemic, depression scores were not significantly different between PwNID and controls, although a higher proportion of PwNID reported clinically significant depression at study entry. Depression scores did not worsen over time for either group. Loneliness was the strongest predictor of worse depression, along with older age, male gender in both PwNID and controls, as well as lack of disease modifying therapy use, and disease duration in PwNID only. In contrast, physical disability worsened significantly over time for both PwNID and controls. Age, DMT status and comorbid health conditions emerged as significant predictors of physical function.

Conclusions: Depressive symptoms remained consistent for both PwNID and controls throughout the COVID-19 pandemic, but physical function worsened significantly over time for both groups. This is particularly impactful for PwNID, who have higher baseline levels of physical disability, and underscores the importance of reinstituting services and interventions that facilitate exercise and reconditioning for this population.

Keywords: COVID19; Depression; Multiple sclerosis.

MeSH terms

  • COVID-19* / epidemiology
  • Depression / epidemiology
  • Humans
  • Male
  • Neuroinflammatory Diseases
  • Pandemics*
  • SARS-CoV-2